The maker of an crucial addiction treatment medicine has agreed to fork out $102 million pounds to settle claims it stifled competition. Indivior would make Suboxone, which decreases drug cravings in folks with opioid use condition.

The Virginia-based mostly Indivior introduced Suboxone in 2002 and then, according to condition lawyers general, employed “monopolistic” procedures to maintain generic versions of the opioid-cure medicine off the industry.

New York Attorney Normal Letitia James unveiled a statement expressing Indivior “selfishly maneuvered to hold less pricey variations of a lifestyle-conserving drug out of the fingers of millions of Individuals” as the opioid crisis grew.

States sued the firm in 2016. This settlement with 41 states and the District of Columbia ends that authorized combat.

In a assertion, Indivior admitted no wrongdoing and reported this offer makes it possible for the organization to emphasis on individual treatment.

“We acquire our role as a dependable steward of medications for addiction and rescue incredibly seriously,” said Indivior CEO Mark Crossley. “Resolving these legacy issues at the right price makes it possible for us to further this mission for clients.”

Firm officials reported they hope to spend the $102.5 million from dollars on hand afterwards this thirty day period.